Ocugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026
Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for